Preclinical Imaging In Vivo Market Advances with AI Innovations and Multimodal Systems, Poised for Steady Expansion Through 2031

United States of America – December 19, 2025 – According to The Insight Partners, The Preclinical Imaging In Vivo Market size is expected to reach US$ 1.82 Billion by 2031. The market is anticipated to register a CAGR of 6.5% during 2025-2031. Researchers and pharmaceutical leaders increasingly turn to preclinical imaging in vivo technologies for non-invasive insights into disease models and drug responses, accelerating discovery timelines in vital fields like oncology and neurology. Breakthroughs from Bruker Corporation and Revvity, Inc., including AI-enhanced analysis tools, are reshaping preclinical imaging in vivo workflows for greater precision and speed.​

This surge reflects a broader commitment to bridging preclinical imaging in vivo gaps between lab experiments and clinical outcomes, empowering global biotech innovation amid rising chronic disease burdens. As demand grows for real-time, high-resolution visualization in animal models, preclinical imaging in vivo stands as a cornerstone for efficient drug development.​

Get a Sample Copy At - https://www.theinsightpartners.com/sample/TIPMD00002567/

Market Overview and Growth Drivers

Preclinical imaging in vivo encompasses cutting-edge modalities such as optical imaging systems, nuclear imaging systems, and micro-MRI systems, allowing scientists to monitor living biological processes without harm to animal subjects. These tools track cellular dynamics, evaluate therapeutic responses, and optimize candidates for human trials, proving indispensable in modern biomedical research.​

Major growth drivers include heightened pharmaceutical R&D investments, expansion of contract research organizations, and the push for hybrid multimodal platforms that merge optical, nuclear, and MRI data for richer insights. Revvity's September 2025 Synergy AI software launch exemplifies this, integrating analysis across optical, microCT, and ultrasound to slash manual processing time and elevate reproducibility in preclinical imaging in vivo studies.​

Bruker Corporation's April 2025 benchtop single-cell system further democratizes advanced preclinical imaging in vivo for immuno-oncology and cell therapies, leveraging microfluidics and machine learning for unprecedented accessibility. These innovations address key pain points like data overload and operator variability, fueling a shift toward automated, sensitive preclinical imaging in vivo solutions.​

Key Segments in Preclinical Imaging In Vivo

Preclinical imaging in vivo divides into core modalities and supporting reagents, each tailored to specific research demands. Optical imaging systems dominate for their affordability in fluorescence and bioluminescence tracking, perfect for real-time tumor monitoring, while nuclear systems like PET and SPECT shine in metabolic profiling.​

Micro-MRI systems deliver superior soft-tissue resolution for brain and cardiac studies. Complementing these, preclinical optical imaging reagents facilitate molecular visualization, nuclear imaging reagents enable radionuclide precision, MRI contrast agents boost anatomical detail, and CT contrast agents ensure structural accuracy.​

Market leaders including Takara Bio, Bruker Biospin, Carestream Health, PerkinElmer, Evrogen, Agilent Technologies, BD Biosciences, Berthold Technologies, and GE Healthcare drive progress via innovative portfolios and partnerships. Bruker's hybrid systems and PerkinElmer's reagent suites solidify their preclinical imaging in vivo leadership, with recent collaborations enhancing global accessibility.​

Market Size, Share, Trends, Analysis, and Forecast to 2031

The preclinical imaging in vivo market is projected to reach US$ 1.82 Billion by 2031, growing at a 6.5% CAGR from 2025 to 2031, underscoring its vital role in research acceleration.​

• Global Trends: AI-powered processing delivers rapid insights, multimodal hybrids provide comprehensive data fusion, and low-radiation sustainable options align with ethical research standards amid chronic disease rises.​
• Share Analysis: North America holds the top share thanks to robust R&D funding and pharma dominance, Europe leverages academic collaborations, Asia-Pacific accelerates via CRO growth in China and India.​
• Regional Analysis: North America's oncology focus thrives on precision medicine; Europe's regulatory frameworks spur hybrid adoption; Asia-Pacific's infrastructure boom in Japan and Southeast Asia promises fastest gains; Latin America and Middle East & Africa emerge via international partnerships and rising investments.​
• Forecast to 2031: Chronic disease research propels optical and nuclear leadership, with emerging regions adding substantial incremental growth through affordable tech adoption and policy support.​

These elements highlight preclinical imaging in vivo's trajectory toward broader integration in drug discovery worldwide.​

Purchasing This Report? Click Here At - https://www.theinsightpartners.com/buy/TIPMD00002567/

If you have any special requirements about this Preclinical Imaging In Vivo Market report, please let us know and we can provide custom report.

Industry Impact and Future Outlook

Preclinical imaging in vivo revolutionizes pipelines by enabling longitudinal studies that reduce animal numbers and heighten clinical predictivity. Persistent hurdles like equipment costs and expertise gaps yield to compact, intuitive designs and training programs.​

MR Solutions' May 2025 7T SPECT/MR-PET installation at Houston Methodist advances high-field multimodal capabilities for intricate models in cardiology and neurodegeneration. Meanwhile, FUJIFILM Holdings and Mediso Ltd. push high-resolution boundaries, complementing leaders in diverse applications.​

Pharma firms, CROs, and academia gain from preclinical imaging in vivo's reproducible metrics, informing data-driven decisions. With AI, sustainability, and regional expansions intensifying, preclinical imaging in vivo cements its status as biomedical innovation's backbone through 2031 and beyond.​

Related Reports

• Pre Clinical Imaging Market Growth, Analysis, and Forecast by 2031
• Clinical Trial Imaging Market Analysis and Opportunities by 2028
• Bio-imaging Market Analysis, Regional and Competitive Landscape Forecast by 2031

About The Insight Partners

The Insight Partners is among the leading market research and consulting firms in the world. We take pride in delivering exclusive reports along with sophisticated strategic and tactical insights into the industry. Reports are generated through a combination of primary and secondary research, solely aimed at giving our clientele a knowledge-based insight into the market and domain. This is done to assist clients in making wiser business decisions. A holistic perspective in every study undertaken forms an integral part of our research methodology and makes the report unique and reliable.

Contact Us:

If you have any queries about this report or if you would like further information, please get in touch with us:

Contact Person: Ankit Mathur

E-mail: ankit.mathur@theinsightpartners.com

Phone: +1-646-491-9876

Also Available in: 日本 | 한국어 | Français | لعربية< | 中文 | Italiano | Español | Deutsch